Study on the molecular mechanism of dihydromyricetin in alleviating liver cirrhosis based on network pharmacology

Abstract

AbstractDihydromyricetin (DHM) is a bioactive flavonoid extracted from Hovenia dulcis, which has various activities. In the present study, the molecular mechanism of dihydromyricetin (DHM) in relieving liver cirrhosis was investigated through network pharmacology and experimental verification. The cell model was induced by TGF‐β1 activating the human hepatic stellate cell line (HSC; LX‐2). The protein levels of α‐SMA, collagen I, and collagen III and pathway‐related proteins within LX‐2 cells were detected using Western blot. EdU staining was conducted to detect cell proliferation. Immunofluorescence staining was performed to detect the expression levels of α‐SMA and collagen I. Next, the drug targets of DHM were screened from the PubChem database. The differentially expressed genes in the liver cirrhosis dataset GSE14323 were identified. The expression of the identified drug targets in LX‐2 cells was verified using qRT‐PCR. The results showed that TGF‐β1 treatment notably increased LX‐2 cell viability, promoted cell proliferation, and elevated α‐SMA, collagen I, and collagen III protein contents. DHM treatment could partially eliminate TGF‐β1 effects, as evidenced by the inhibited cell viability and proliferation and reduced α‐SMA, collagen I, and collagen III contents. After network pharmacology analysis, nine differentially expressed target genes (MMP2, PDGFRB, PARP1, BCL2L2, ABCB1, TYR, CYP2E1, SQSTM1, and IL6) in liver cirrhosis were identified. According to qRT‐PCR verification, DHM could inhibit the expression of MMP2, PDGFRB, PARP1, CYP2E1, SQSTM1, and IL6, and enhance ABCB1 expression levels within LX‐2 cells. Moreover, DHM inhibited mTOR and MAPK signaling pathways in TGF‐β1‐induced HSCs. In conclusion, DHM could inhibit HSC activation, which may be achieved via acting on MMP2, PDGFRB, PARP1, CYP2E1, SQSTM1, IL6, and ABCB1 genes and their downstream signaling pathways, including mTOR and MAPK signaling pathway.